Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.

Fujii, Tomoko; Luethi, Nora; Young, Paul J; Frei, Daniel R; Eastwood, Glenn M; French, Craig J; Deane, Adam M; Shehabi, Yahya; Hajjar, Ludhmila A; Oliveira, Gisele; Udy, Andrew A; Orford, Neil; Edney, Samantha J; Hunt, Anna L; Judd, Harriet L; Bitker, Laurent; Cioccari, Luca; Naorungroj, Thummaporn; Yanase, Fumitaka; Bates, Samantha; ... (2020). Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. (In Press). JAMA : the journal of the American Medical Association American Medical Association 10.1001/jama.2019.22176

[img] Text
2020 - Fujii - JAMA - PMID 31950979.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (480kB) | Request a copy

Importance It is unclear whether vitamin C, hydrocortisone, and thiamine are more effective than hydrocortisone alone in expediting resolution of septic shock. Objective To determine whether the combination of vitamin C, hydrocortisone, and thiamine, compared with hydrocortisone alone, improves the duration of time alive and free of vasopressor administration in patients with septic shock. Design, Setting, and Participants Multicenter, open-label, randomized clinical trial conducted in 10 intensive care units in Australia, New Zealand, and Brazil that recruited 216 patients fulfilling the Sepsis-3 definition of septic shock. The first patient was enrolled on May 8, 2018, and the last on July 9, 2019. The final date of follow-up was October 6, 2019. Interventions Patients were randomized to the intervention group (n = 109), consisting of intravenous vitamin C (1.5 g every 6 hours), hydrocortisone (50 mg every 6 hours), and thiamine (200 mg every 12 hours), or to the control group (n = 107), consisting of intravenous hydrocortisone (50 mg every 6 hours) alone until shock resolution or up to 10 days. Main Outcomes and Measures The primary trial outcome was duration of time alive and free of vasopressor administration up to day 7. Ten secondary outcomes were prespecified, including 90-day mortality. Results Among 216 patients who were randomized, 211 provided consent and completed the primary outcome measurement (mean age, 61.7 years [SD, 15.0]; 133 men [63%]). Time alive and vasopressor free up to day 7 was 122.1 hours (interquartile range [IQR], 76.3-145.4 hours) in the intervention group and 124.6 hours (IQR, 82.1-147.0 hours) in the control group; the median of all paired differences was -0.6 hours (95% CI, -8.3 to 7.2 hours; P = .83). Of 10 prespecified secondary outcomes, 9 showed no statistically significant difference. Ninety-day mortality was 30/105 (28.6%) in the intervention group and 25/102 (24.5%) in the control group (hazard ratio, 1.18; 95% CI, 0.69-2.00). No serious adverse events were reported. Conclusions and Relevance In patients with septic shock, treatment with intravenous vitamin C, hydrocortisone, and thiamine, compared with intravenous hydrocortisone alone, did not significantly improve the duration of time alive and free of vasopressor administration over 7 days. The finding suggests that treatment with intravenous vitamin C, hydrocortisone, and thiamine does not lead to a more rapid resolution of septic shock compared with intravenous hydrocortisone alone. Trial Registration ClinicalTrials.gov Identifier: NCT03333278.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Intensive Care, Emergency Medicine and Anaesthesiology (DINA) > Clinic of Intensive Care

UniBE Contributor:

Cioccari, Luca

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1538-3598

Publisher:

American Medical Association

Language:

English

Submitter:

Mirella Aeberhard

Date Deposited:

07 Feb 2020 14:32

Last Modified:

07 Feb 2020 14:32

Publisher DOI:

10.1001/jama.2019.22176

PubMed ID:

31950979

BORIS DOI:

10.7892/boris.139285

URI:

https://boris.unibe.ch/id/eprint/139285

Actions (login required)

Edit item Edit item
Provide Feedback